| Name | Title | Contact Details |
|---|
Delfi is developing a new class of liquid biopsy tests for early detection based on altered genome-wide fragmentation profiles, also known as "fragmentomes," representing aberrant packaging of DNA in cancer cells. By applying advanced machine learning algorithms, these fragment patterns are detectable at a very low sequencing cost. Delfi is using this technology to develop highly sensitive and specific cancer detection assays intended for wide and cost-effective distribution and adoption.
Bayer AG is a Baytown, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Expansion Therapeutics is a drug discovery and development company pursuing the vast potential of small molecule medicines for RNA-mediated diseases.
AiLife Diagnostics is a CAP/CLIA laboratory that provides end-to-end genomic testing, interpretation services, and NGS analysis tool.
AmProx is a Carlsbad, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.